Kymera Therapeutics, Inc.KYMREarnings & Financial Report
Kymera Therapeutics is a clinical-stage biopharmaceutical company specialized in developing innovative targeted protein degradation therapies. It advances a diversified pipeline of drug candidates targeting previously undruggable proteins to address unmet medical needs in oncology, autoimmune and inflammatory diseases worldwide.
KYMR Q2 FY2025 Key Financial Metrics
Revenue
$11.5M
Gross Profit
$0
Operating Profit
$-84.6M
Net Profit
$-76.6M
Gross Margin
N/A
Operating Margin
-736.8%
Net Margin
-667.6%
YoY Growth
-55.3%
EPS
$-0.95
Kymera Therapeutics, Inc. Q2 FY2025 Financial Summary
Kymera Therapeutics, Inc. reported revenue of $11.5M (down 55.3% YoY) for Q2 FY2025, with a net profit of $-76.6M (down 82.1% YoY) (-667.6% margin). Cost of goods sold was $11.5M, operating expenses totaled $84.6M.
Key Financial Metrics
| Total Revenue | $11.5M |
|---|---|
| Net Profit | $-76.6M |
| Gross Margin | N/A |
| Operating Margin | -736.8% |
| Report Period | Q2 FY2025 |
Kymera Therapeutics, Inc. Annual Revenue by Year
Kymera Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2022 revenue was $46.8M).
| Year | Annual Revenue | |
|---|---|---|
| 2022 | $46.8M | — |
Kymera Therapeutics, Inc. Quarterly Revenue & Net Profit History
Kymera Therapeutics, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q2 FY2025 | $11.5M | -55.3% | $-76.6M | -667.6% |
| Q1 FY2025 | $22.1M | +114.8% | $-65.6M | -296.7% |
| Q4 FY2024 | $7.4M | -84.6% | $-70.8M | -956.9% |
| Q2 FY2024 | $25.6M | +55.3% | $-42.1M | -164.0% |
| Q1 FY2024 | $10.3M | +8.7% | $-48.6M | -472.0% |
| Q4 FY2023 | $47.9M | +196.7% | $-14.4M | -30.0% |
| Q2 FY2023 | $16.5M | +43.4% | $-38.8M | -235.0% |
| Q1 FY2023 | $9.5M | -1.6% | $-40.9M | -432.4% |
Income Statement
| Q1 2023 | Q2 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q4 2024 | Q1 2025 | Q2 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $9.5M | $16.5M | $47.9M | $10.3M | $25.6M | $7.4M | $22.1M | $11.5M |
| YoY Growth | -1.6% | 43.4% | 196.7% | 8.7% | 55.3% | -84.6% | 114.8% | -55.3% |
Balance Sheet
| Q1 2023 | Q2 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q4 2024 | Q1 2025 | Q2 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $613.9M | $581.9M | $575.8M | $868.3M | $826.0M | $978.0M | $918.3M | $1.13B |
| Liabilities | $151.9M | $146.5M | $180.8M | $157.0M | $141.1M | $142.4M | $132.1M | $159.6M |
| Equity | $462.0M | $435.4M | $395.0M | $711.2M | $684.9M | $835.6M | $786.2M | $971.5M |
Cash Flow
| Q1 2023 | Q2 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q4 2024 | Q1 2025 | Q2 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-44.0M | $-35.3M | $8.0M | $-39.6M | $-42.9M | $-61.8M | $-79.2M | $-59.9M |